Low frequency of CD3+CD4+CD161+ T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
Sign Up to like & getrecommendations! Published in 2018 at "Annals of Hematology"
DOI: 10.1007/s00277-018-3401-y
Abstract: The aim of this study was to explore the predictive implications of the composition of immune cell populations prior to lenalidomide plus high-dose dexamethasone (Len-Dex) initiation for the occurrence of infections. We prospectively examined immune… read more here.
Keywords: cd3 cd4; dex; lenalidomide plus; occurrence infections ... See more keywords
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Management and Research"
DOI: 10.2147/cmar.s309092
Abstract: Background This study explored the efficacy of lenalidomide plus rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) including cases of secondary central nervous system (CNS) involvement and transformed follicular lymphoma (FL)… read more here.
Keywords: response; plus rituximab; lymphoma; relapsed refractory ... See more keywords
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2018.194399
Abstract: TP53 mutations are associated with significant poorer outcomes in mantle cell lymphoma (MCL), and new treatment strategies are highly warranted. Lenalidomide has shown high efficacy in MCL; however, there is no knowledge of its effect… read more here.
Keywords: plus bendamustine; lenalidomide plus; mantle cell; tp53 ... See more keywords